-
Cholesteryl ester-transfer protein inhibitors stimulate aldosterone biosynthesis in adipocytes through Nox-dependent processes.
The Journal of pharmacology and experimental therapeutics 20150401
-
Future of cholesteryl ester transfer protein inhibitors.
Annual review of medicine 20140101
-
Solubility and stability of dalcetrapib in vehicles and biological media.
International journal of pharmaceutics 20121101
-
Evidence of a drug-drug interaction linked to inhibition of ester hydrolysis by orlistat.
Journal of cardiovascular pharmacology 20121001
-
Tangier disease: epidemiology, pathophysiology, and management.
American journal of cardiovascular drugs : drugs, devices, and other interventions 20121001
-
Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk.
Journal of lipid research 20120901
-
Dalcetrapib , a cholesteryl ester transfer protein modulator.
Expert opinion on investigational drugs 20120901
-
Rationale for cholesteryl ester transfer protein inhibition.
Current opinion in lipidology 20120801
-
HDL and CETP Inhibition: Will This DEFINE the Future?
Current treatment options in cardiovascular medicine 20120801
-
Lipid and apoprotein composition of HDL in partial or complete CETP deficiency.
Current vascular pharmacology 20120701
-
Determination of dalcetrapib by liquid chromatography-tandem mass spectrometry.
Journal of pharmaceutical and biomedical analysis 20120701
-
Increasing high-density lipoprotein cholesterol by cholesteryl ester transfer protein-inhibition: a rocky road and lessons learned? The early demise of the dal-HEART programme.
European heart journal 20120701
-
An update on the clinical development of dalcetrapib (RO4607381), a cholesteryl ester transfer protein modulator that increases HDL cholesterol levels.
Future cardiology 20120701
-
Current status of CETP inhibitors in the treatment of hyperlipidemia: an update.
Current clinical pharmacology 20120501
-
Design, synthesis and structure-activity-relationship of 1,5-tetrahydronaphthyridines as CETP inhibitors.
Bioorganic & medicinal chemistry letters 20120501
-
Dalcetrapib--restoring belief in modulating CETP as a beneficial mechanism in cardiovascular disease.
Expert opinion on investigational drugs 20120401
-
Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial.
European heart journal 20120401
-
Cholesteryl ester transfer protein inhibition and endothelial function: enough with the surrogates.
European heart journal 20120401
-
No clinically relevant drug-drug interactions when dalcetrapib is co-administered with a monophasic oral contraceptive (Microgynon® 30).
International journal of clinical pharmacology and therapeutics 20120401
-
Monitoring Cyp2b10 mRNA expression at cessation of 2-year carcinogenesis bioassay in mouse liver provides evidence for a carcinogenic mechanism devoid of human relevance: the dalcetrapib experience.
Toxicology and applied pharmacology 20120315
-
Pharmacotherapy. Elevating HDL-cholesterol levels with dalcetrapib is safe.
Nature reviews. Cardiology 20120306
-
On- and off-target pharmacology of torcetrapib: current understanding and implications for the structure activity relationships (SAR), discovery and development of cholesteryl ester-transfer protein (CETP) inhibitors.
Drugs 20120305
-
Effect of dalcetrapib plus pravastatin on lipoprotein metabolism and high-density lipoprotein composition and function in dyslipidemic patients: results of a phase IIb dose-ranging study.
American heart journal 20120301
-
CETP inhibition in perspective.
Atherosclerosis 20120201
-
New horizons for cholesterol ester transfer protein inhibitors.
Current atherosclerosis reports 20120201
-
Efficacy and safety of dalcetrapib in type 2 diabetes mellitus and/or metabolic syndrome patients, at high cardiovascular disease risk.
Diabetes, obesity & metabolism 20120101
-
Lipid exchange mechanism of the cholesteryl ester transfer protein clarified by atomistic and coarse-grained simulations.
PLoS computational biology 20120101
-
Regulation of reverse cholesterol transport - a comprehensive appraisal of available animal studies.
Nutrition & metabolism 20120101
-
Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases.
Vascular health and risk management 20120101
-
Mipomersen: evidence-based review of its potential in the treatment of homozygous and severe heterozygous familial hypercholesterolemia.
Core evidence 20120101
-
Cholesteryl ester transfer protein inhibitors for dyslipidemia: focus on dalcetrapib.
Drug design, development and therapy 20120101
-
Lipids, blood pressure, kidney - what was new in 2011?
Archives of medical science : AMS 20111231
-
[Secondary coronary heart disease prevention. Will CEPT inhibitors be the next breakthrough?].
MMW Fortschritte der Medizin 20111208
-
Cholesteryl ester transfer protein inhibition in cardiovascular risk management: ongoing trials will end the confusion.
Cardiovascular therapeutics 20111201
-
Familial hypercholesterolemia: present and future management.
Current cardiology reports 20111201
-
Multidimensional profiling of plasma lipoproteins by size exclusion chromatography followed by reverse-phase protein arrays.
Journal of lipid research 20111201
-
Effect of dalcetrapib, a CETP modulator, on non-cholesterol sterol markers of cholesterol homeostasis in healthy subjects.
Atherosclerosis 20111201
-
Cholesteryl ester transfer protein inhibition to reduce cardiovascular risk: Where are we now?
Trends in pharmacological sciences 20111201
-
Therapy and clinical trials.
Current opinion in lipidology 20111201
-
Investigational CETP antagonists for hyperlipidemia and atherosclerosis prevention.
Expert opinion on investigational drugs 20111101
-
Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial.
Lancet (London, England) 20111029
-
Dalcetrapib: turning the tide for CETP inhibition?
Lancet (London, England) 20111029
-
Anacetrapib: hope for CETP inhibitors?
Cardiovascular therapeutics 20111001
-
Coronary artery disease: Dalcetrapib safely raises HDL-cholesterol level in the phase IIb dal-PLAQUE trial.
Nature reviews. Cardiology 20110927
-
Different effects of compounds decreasing cholesteryl ester transfer protein activity on lipoprotein metabolism.
Current opinion in lipidology 20110801
-
Rationale and design of dal-PLAQUE: a study assessing efficacy and safety of dalcetrapib on progression or regression of atherosclerosis using magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography/computed tomography.
American heart journal 20110801
-
Utility of atherosclerosis imaging in the evaluation of high-density lipoprotein-raising therapies.
Current atherosclerosis reports 20110601
-
Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management.
European heart journal 20110601
-
Effects of food intake on the pharmacokinetic properties of dalcetrapib: findings from three phase I, single-dose crossover studies in healthy volunteers.
Clinical therapeutics 20110601
-
[Cholesteryl ester transfer protein inhibition in the management of atherosclerotic cardiovascular disease: second act 'A rebirth of hope'].
Revista medica de Chile 20110601
-
Dalcetrapib pharmacokinetics and metabolism in the cynomolgus monkey.
Xenobiotica; the fate of foreign compounds in biological systems 20110501
-
Learning lessons from Pfizer's $800 million failure.
Nature reviews. Drug discovery 20110301
-
Rationale and design of dal-VESSEL: a study to assess the safety and efficacy of dalcetrapib on endothelial function using brachial artery flow-mediated vasodilatation.
Current medical research and opinion 20110101
-
Anacetrapib and dalcetrapib: two novel cholesteryl ester transfer protein inhibitors.
The Annals of pharmacotherapy 20110101
-
[Novel therapy for atherosclerosis and inflammatory vascular disease].
Nihon rinsho. Japanese journal of clinical medicine 20110101
-
Safety, tolerability and pharmacokinetics of dalcetrapib following single and multiple ascending doses in healthy subjects: a randomized, double-blind, placebo-controlled, phase I study.
Clinical drug investigation 20110101
-
Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey.
Drug design, development and therapy 20110101
-
Where are we heading with noninvasive clinical vascular physiology? Why and how should we assess endothelial function?
Cardiology research and practice 20110101
-
Emerging therapeutic strategies to enhance HDL function.
Lipids in health and disease 20110101
-
Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport.
Journal of lipid research 20101201
-
Lack of clinically relevant drug-drug interactions when dalcetrapib is co-administered with ezetimibe.
British journal of clinical pharmacology 20101201
-
Good news for 'good' cholesterol.
Nature 20101118
-
Coadministration of dalcetrapib with pravastatin, rosuvastatin, or simvastatin: no clinically relevant drug-drug interactions.
Journal of clinical pharmacology 20101001
-
No clinically relevant drug-drug interactions when dalcetrapib is co-administered with atorvastatin.
Expert opinion on investigational drugs 20101001
-
Emerging drugs for hyperlipidemia.
Expert opinion on emerging drugs 20100901
-
Biochemical characterization of cholesteryl ester transfer protein inhibitors.
Journal of lipid research 20100901
-
Mechanisms underlying off-target effects of the cholesteryl ester transfer protein inhibitor torcetrapib involve L-type calcium channels.
Journal of hypertension 20100801
-
Lack of effect of dalcetrapib on QT interval in healthy subjects following multiple dosing.
European journal of clinical pharmacology 20100801
-
Is a blood pressure rise the only deleterious off-target effect of cholesterol ester transfer protein inhibitors?
Journal of hypertension 20100801
-
Dissociating HDL cholesterol from cardiovascular risk.
Lancet (London, England) 20100731
-
Dalcetrapib: a review of Phase II data.
Expert opinion on investigational drugs 20100601
-
High-density lipoprotein-mediated anti-atherosclerotic and endothelial-protective effects: a potential novel therapeutic target in cardiovascular disease.
Current pharmaceutical design 20100501
-
Dalcetrapib: JTT 705; JTT-705; R 1658; R1658; RG1658; RO 4607381; RO4607381.
Drugs in R&D 20100501
-
MARCO, a macrophage scavenger receptor highly expressed in rodents, mediates dalcetrapib-induced uptake of lipids by rat and mouse macrophages.
Toxicology in vitro : an international journal published in association with BIBRA 20100401
-
[HDL and CETP in atherogenesis].
Deutsche medizinische Wochenschrift (1946) 20100201
-
Functional assessment of HDL: Moving beyond static measures for risk assessment.
Cardiovascular drugs and therapy 20100201
-
Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial.
European heart journal 20100201
-
Mulling over the odds of CETP inhibition.
European heart journal 20100201
-
Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors.
European heart journal 20100101
-
Insights from recent meta-analysis: role of high-density lipoprotein cholesterol in reducing cardiovascular events and rates of atherosclerotic disease progression.
Journal of clinical lipidology 20100101
-
Update on CETP inhibition.
Journal of clinical lipidology 20100101
-
Low high-density lipoprotein cholesterol: current status and future strategies for management.
Vascular health and risk management 20100101
-
High density lipoproteins-based therapies for cardiovascular disease.
Journal of cardiovascular disease research 20100101
-
Dalcetrapib: no off-target toxicity on blood pressure or on genes related to the renin-angiotensin-aldosterone system in rats.
British journal of pharmacology 20091201
-
Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome.
American heart journal 20091201
-
The pharmacology and off-target effects of some cholesterol ester transfer protein inhibitors.
The American journal of cardiology 20091116
-
Mechanism of inhibition defines CETP activity: a mathematical model for CETP in vitro.
Journal of lipid research 20091101
-
Cholesteryl ester transfer protein inhibitors as high-density lipoprotein raising agents.
Expert opinion on therapeutic patents 20090901
-
Anacetrapib, a cholesterol ester transfer protein (CETP) inhibitor for the treatment of atherosclerosis.
Current opinion in investigational drugs (London, England : 2000) 20090901
-
Gateways to clinical trials.
Methods and findings in experimental and clinical pharmacology 20090901
-
Free thiol group of MD-2 as the target for inhibition of the lipopolysaccharide-induced cell activation.
The Journal of biological chemistry 20090717
-
The end of the road for CETP inhibitors after torcetrapib?
Current opinion in cardiology 20090701
-
Safety and tolerability of dalcetrapib.
The American journal of cardiology 20090701
-
In vitro and in vivo assessment of the effect of dalcetrapib on a panel of CYP substrates.
Current medical research and opinion 20090401
-
A single-center, open-label, one-sequence study of dalcetrapib coadministered with ketoconazole, and an in vitro study of the S-methyl metabolite of dalcetrapib.
Clinical therapeutics 20090301
-
Cholesterylestertransfer protein inhibition and endothelial function in type II hyperlipidemia.
Thrombosis research 20090101
-
JTT-705: is there still future for a CETP inhibitor after torcetrapib?
Expert opinion on investigational drugs 20081001
-
Gateways to clinical trials.
Methods and findings in experimental and clinical pharmacology 20080501
-
Cholesteryl ester transfer protein inhibition and HDL increase: has the dream ended?
Expert opinion on investigational drugs 20080401
-
Is raising HDL a futile strategy for atheroprotection?
Nature reviews. Drug discovery 20080201
-
HDL metabolism and CETP inhibition.
Cardiology in review 20080101
-
Gateways to clinical trials. July-August 2008.
Methods and findings in experimental and clinical pharmacology 20080101
-
The role of CETP inhibition in dyslipidemia.
Current atherosclerosis reports 20070801
-
The biology and chemistry of hyperlipidemia.
Bioorganic & medicinal chemistry 20070715
-
Cholesteryl ester transfer protein promotes the formation of cholesterol-rich remnant like lipoprotein particles in human plasma.
Clinica chimica acta; international journal of clinical chemistry 20070101
-
Inhibition of CETP as a novel therapeutic strategy for reducing the risk of atherosclerotic disease.
European heart journal 20070101
-
Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease.
Pharmacology & therapeutics 20060901
-
Cholesteryl ester transfer protein inhibition, high-density lipoprotein metabolism and heart disease risk reduction.
Current opinion in lipidology 20060801
-
Are human CETP mutations and CETP-inhibiting drugs a good or a bad deal?
Journal of molecular medicine (Berlin, Germany) 20060801
-
Raising high-density lipoprotein with cholesteryl ester transfer protein inhibitors.
Current opinion in pharmacology 20060401
-
Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease.
Journal of the American College of Cardiology 20060207
-
Increasing high-density lipoprotein cholesterol through cholesteryl Ester transfer protein inhibition: a next step in the fight against cardiovascular disease?
Current drug targets. Cardiovascular & haematological disorders 20051201
-
JTT-705 blocks cell proliferation and angiogenesis through p38 kinase/p27(kip1) and Ras/p21(waf1) pathways.
Atherosclerosis 20051001
-
Consequences of cholesteryl ester transfer protein inhibition in patients with familial hypoalphalipoproteinemia.
Arteriosclerosis, thrombosis, and vascular biology 20050901
-
Pharmacologic augmentation of high-density lipoproteins: mechanisms of currently available and emerging therapies.
Current opinion in cardiology 20050701
-
Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia.
The American journal of cardiology 20050501
-
Role of CETP inhibitors in the treatment of dyslipidemia.
Current opinion in lipidology 20041201
-
Inhibition of cholesteryl ester transfer protein activity by JTT-705 increases apolipoprotein E-containing high-density lipoprotein and favorably affects the function and enzyme composition of high-density lipoprotein in rabbits.
Arteriosclerosis, thrombosis, and vascular biology 20041001
-
S-(2-(acylamino)phenyl) 2,2-dimethylpropanethioates as CETP inhibitors.
Bioorganic & medicinal chemistry letters 20040517
-
JTT-705. Japan Tobacco.
Current opinion in investigational drugs (London, England : 2000) 20040301
-
Inhibition of cholesteryl ester transfer protein increases serum apolipoprotein (apo) A-I levels by increasing the synthesis of apo A-I in rabbits.
Atherosclerosis 20040201
-
Dual effects on HDL metabolism by cholesteryl ester transfer protein inhibition in HepG2 cells.
American journal of physiology. Endocrinology and metabolism 20030601
-
Effect of JTT-705 on cholesteryl ester transfer protein and plasma lipid levels in normolipidemic animals.
European journal of pharmacology 20030411
-
Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis.
Arteriosclerosis, thrombosis, and vascular biology 20030201
-
Cholesteryl ester transfer protein inhibitor (JTT-705) and the development of atherosclerosis in rabbits with severe hypercholesterolaemia.
Clinical science (London, England : 1979) 20021201
-
The Yin and Yang of cholesteryl ester transfer protein and atherosclerosis.
Clinical science (London, England : 1979) 20021201
-
Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study.
Circulation 20020507
-
Effect of HDL, from Japanese white rabbit administered a new cholesteryl ester transfer protein inhibitor JTT-705, on cholesteryl ester accumulation induced by acetylated low density lipoprotein in J774 macrophage.
Atherosclerosis 20020501
-
[CETP inhibitor].
Nihon rinsho. Japanese journal of clinical medicine 20010301